MERIDIANDECISION INTELLIGENCEOwner deskOwnerPublic screen
My judgments
MERIDIAN / EXPLORE

From a question,
to the next decision.

View

Skin

YOUR DECISION WORKSPACEOwner onlyStart a new question Open my judgments →Owner operations desk →
Owner sign-in →Signed in as the ownerSign out — see what a visitor sees →End the Cloudflare Access session too →
Reading language
The screen, the questions and the judgments read in English where an English reading has been made. The Korean originals are unchanged, and evidence stays in the language it was written in.

Study · from IATHEON's records

A Model in Place of an Animal: Who Accepts In-Silico Evidence, by When, and What Reopens It

United States law now lets a computer model count as a nonclinical test, yet the same texts leave the evidence standard unchanged and the acceptance of any model to the agency, one context of use at a time. This short study reads eleven public texts, from the Cures Act to the FDA's 2025 plan and the literature on model credibility, to ask who decides when in-silico evidence may stand in for animal or clinical evidence, by when, and what would make them look again.

Source
IATHEON
Cases
0
Length
about 10,000 words
As of
2026-10-07

By RISCON Labs AI from public-domain and openly licensed sources on in-silico drug discovery · not medical advice · the readings through the works named are this study's interpretation · First edition · October 2026

Start readingThe records at IATHEON
AI-generated editorial illustration: A model vessel faces a laboratory testing chamber across an unconnected gap.

Contents

Before

  1. Abstract1 min
  2. Introduction7 min

Part I · A Model in Place of an Animal: Who Accepts In-Silico Evidence, by When, and What Reopens It

  1. Chapter 1. Who Decides, by When, and What Reopens It16 min
  2. Chapter 2. Appendix: The sources read9 min

After

  1. Conclusion6 min
  2. Sources and bibliography3 min
RISCON Labsrisconlabs.com